Adrian Kilcoyne Selected Research

lenzilumab

1/2023	C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 'LIVE-AIR' trial.
1/2022	Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective.
1/2022	Clinical and Economic Benefits of Lenzilumab Plus Standard of Care Compared with Standard of Care Alone for the Treatment of Hospitalized Patients with Coronavirus Disease 19 (COVID-19) from the Perspective of National Health Service England.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Adrian Kilcoyne Research Topics

Disease

3	COVID-19 01/2023 - 01/2022
1	Pain (Aches) 11/2023
1	Pneumonia (Pneumonitis) 01/2022
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2021

Drug/Important Bio-Agent (IBA)

3	lenzilumabIBA 01/2023 - 01/2022
1	Proteins (Proteins, Gene)FDA Link 11/2023
1	C-Reactive ProteinIBA 01/2023
1	Oxygen (Dioxygen)IBA 01/2023
1	Biomarkers (Surrogate Marker)IBA 01/2023
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2023
1	Monoclonal AntibodiesIBA 01/2023
1	Vincristine (Oncovin)FDA LinkGeneric 01/2021
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021
1	Prednisone (Sone)FDA LinkGeneric 01/2021
1	Rituximab (Mabthera)FDA Link 01/2021
1	Lenalidomide (CC 5013)FDA Link 01/2021
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021

Therapy/Procedure

2	Mechanical Ventilators (Ventilator) 01/2022 - 01/2022
1	Artificial Respiration (Mechanical Ventilation) 01/2023